China Resources Double Crane: Dino-Pregnant Pill Obtains Drug Registration Certificate in Russia.

Announcement from China Resources Shuanghe: Its wholly-owned subsidiary, China Resources Purple Bamboo Pharmaceutical Co., Ltd., has obtained the "Drug Registration Certificate" issued by the Ministry of Health of the Russian Federation for its Dienogest tablets. The drug is used to treat endometriosis, and China Resources Purple Bamboo started the registration process in September 2022, submitted the application for marketing approval in March 2024 and obtained approval. As of the announcement date, the R&D investment was 189,000 RMB. In 2023, global sales of Dienogest tablets reached 365 million USD. In 2024, domestic sales totaled 790 million RMB, with Jenapharm holding a market share of 87.18% and Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd. holding 9.32%. The company's sales revenue for this drug in 2024 was 42,764,900 RMB, with no sales in Russia yet.